Praxis Precision Medicines, Inc.

Ladies and gentlemen, your conference is scheduled to begin momentarily. Please continue to stand by, and thank you for your patience. Thank you. Thank you. Thank you. Thank you. Thank you. THE END

Good day, and welcome to PRAXIS' third quarter 2021 update call. As a reminder, this call may be recorded. I would now like to turn the call over to Alex Kane, Vice President of Investor Relations and Corporate Communications.

Thank you. Good morning, everyone, and thank you for joining us today to discuss PRAXIS' third quarter 2021 corporate update. With me on today's call is our President and Chief Executive Officer, Marcia Souza. our Chief Medical Officer, Bernard Ravina, and our Chief Financial Officer, Tim Kelly. Please note that today's prepared remarks will focus on recent business and pipeline progress, along with a brief update on our third quarter 2021 financial results. We will be referring to supplement slides throughout today's prepared remarks, which are posted on the events and presentation section of our Investor Relations website. So please access them now if you have not already done so. Before we proceed, I would like to remind you that during today's call we will be making certain statements that are beliefs, forward-looking, and subject to various risks and uncertainties. Any statements made during this call that are not statements of historical or current facts are intended to be forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We want to emphasize that such forward-looking statements reflect our current expectations, assumptions, and currently available data regarding, among other things, our business operations, development efforts, and regulatory strategy, and are neither predictions nor guarantees of future events. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with our business. For additional detail on the risk factors associated with our business, I encourage you to consult the detailed forward-looking statement disclaimer on slide two of the supplement slides, as well as our SEC filings. I will now turn the call over to Marcio. Marcio?